Sept. 14: The FDA gave an additional indication to Privigen (immune globulin intravenous [human], 10% liquid) for the treatment of chronic inflammatory demyelinating polyneuropathy in adults. The agency initially approved the CSL Behring AG infusible in 2007; it also is indicated to treat primary humoral immunodeficiency and chronic immune thrombocytopenic purpura. Dosing for the newest […]
To access this post, you must purchase a subscription plan. Click Here to purchase.

Already a member? Click Here to login.